Pharmaceuticals

Astellas Pharma

Astellas Pharma released FY2026 Q4 earnings on April 27 After-Market (EST), actual revenue USD 3.473 B (forecast USD 3.233 B), actual EPS USD 0.2506

Astellas Pharma released FY2026 Annual Earnings on April 27 After-Market EST, actual revenue USD 14.1 B (forecast USD 13.35 B), actual EPS USD 1.0689

Astellas Pharma to Release FY2026 Annual Earnings on April 27 After-Market EST, Forecast Revenue USD 13.43 B

Astellas Pharma released FY2026 Q3 earnings on February 4 After-Market EST, actual revenue USD 3.651 B (forecast USD 3.406 B), actual EPS USD 0.3569

Astellas Pharma released FY2026 9 Months Earnings on February 4 After-Market EST, with actual revenue of USD 10.57 B and actual EPS of USD 0.8154

Astellas Pharma to Release FY2026 Q3 Earnings on February 4 After-Market EST, Forecast Revenue USD 3.42 B

Anstey Pharmaceutical's Zolbetuximab Approved for Scottish NHS

Anthera Pharmaceuticals Completes Phase 3 Study for Non-Hormonal Menopause Drug

Astellas and Pfizer Announce Positive Results from EV-304 Trial

AstraZeneca Announces EMA Validates PADCEV Combination Therapy Application

Astellas Pharma (ADR) Soars in Net Profit by 101% in First Half

Astellas Pharma released FY2026 Q2 earnings on October 30 After-Market EST, actual revenue USD 3.528 B (forecast USD 3.232 B), actual EPS USD 0.2964

Astellas Pharma released FY2026 Semi-Annual Earnings on October 30 After-Market (EST), Actual Revenue: USD 7.023 B (Forecast: USD 6.36 B), Actual EPS: USD 0.5602

Astellas Pharma Raises FY2025 Profit Guidance

Pfizer and Astellas Announce Final Overall Survival Results of XTANDI Combined Therapy for Prostate Cancer Study

Astellas Pharma and Barbara Collaborate to Raise Awareness of GA and Izervay

Astellas Pharma to Release FY2026 Q2 Earnings on October 30 After-Market EST, Forecast Revenue USD 3.25 B

Anthera Pharmaceuticals Releases Preliminary Data from OPTION-VMS Phase IV Study

Pfizer and Astellas Announce XANDI Combined with Lupule Reduces Prostate Cancer Mortality Risk

Acadia Pharmaceuticals Announces Positive Results for IZERVAY™ in AMD Geographic Atrophy Phase 3 Trial

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ALPMY

4503

Astellas Pharma Inc. will present new oncology data at the 2026 ASCO Annual Meeting, highlighting long-term outcomes and clinical applications across various cancer types. Key presentations include a 3.5-year follow-up on enfortumab vedotin for urothelial carcinoma and updates on prostate cancer treatments. Additionally, Astellas will introduce findings on fezolinetant for managing vasomotor symptoms in breast cancer patients. These presentations underscore Astellas' commitment to enhancing cancer care.

- Astellas Pharma will present 10 abstracts, including two oral presentations, at the 2026 ASCO Annual Meeting, highlighting its commitment to oncology research.  
- Key topics include the effectiveness of enfortumab vedotin combined with pembrolizumab for urothelial carcinoma and updates on fezolinetant for managing symptoms in breast cancer patients.  
- These presentations aim to enhance clinical understanding and improve treatment decision-making for various cancer types.

StockTitan

Astellas Pharma Inc.

Pfizer

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | PFE Stock News

TBXU

SBIO

LABU

The Scottish Medicines Consortium has recommended the reimbursement of enfortumab vedotin with pembrolizumab for adults with unresectable or metastatic urothelial cancer. This decision allows access to a treatment that significantly improves overall survival through the NHS. The EV-302 phase 3 trial showed a median overall survival of 33.8 months for the combination compared to 15.9 months for chemotherapy. Experts believe this combination will reshape first-line treatment for advanced bladder cancer patients in Scotland.

PharmaTimes

Direxion Daily Biotech Top 5 Bull 2X ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

SMC backs first-line metastatic bladder cancer combination after trial results

Astellas Pharma Inc. (TSE:4503) reported yearly earnings, with shares dropping 7.8% to JP¥2,306. Revenues met forecasts at JP¥2.1t, but EPS fell short at JP¥163, missing estimates by 4.8%. Analysts forecast revenues of JP¥2.24t for 2027, reflecting a 4.5% growth, while EPS is expected to rise 13% to JP¥184. Despite a downgrade in EPS estimates, the consensus price target remains unchanged at JP¥2,418. Astellas Pharma's growth is projected to align with industry trends, but analysts express varied opinions on the stock's future.

Simplywall

Astellas Pharma Inc. (TSE:4503) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Pfizer and Astellas have received FDA priority review for their Padcev combination therapy for muscle-invasive bladder cancer (MIBC), which aims to expand treatment options for all patients, regardless of cisplatin eligibility. The application is based on Phase III EV-304 trial data, showing a 47% reduction in tumor recurrence risk and a 35% decrease in death risk compared to standard chemotherapy. The FDA's target action date is August 17, 2026. If approved, this therapy could significantly improve patient outcomes in MIBC treatment.

- Pfizer and Astellas have submitted a supplemental biologics license application for perioperative Padcev combined with Keytruda for muscle-invasive bladder cancer, seeking to broaden its use to all patients regardless of cisplatin eligibility.  
- The FDA has accepted the application for priority review, with a target action date of August 17, 2026, based on positive Phase III EV-304 trial data showing significant reductions in tumor recurrence and improved survival rates.  
- The safety profile remained consistent with prior experience, and discussions for regulatory filings with global health authorities are ongoing.

Pharmaceutical Technology

iShares US Pharma

Health Care Select Sector SPDR

VG Health

iShares Global Healthcare

Novavax

Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy

Merck, Pfizer, and Astellas Pharma have received priority review from the FDA for their Keytruda/Padcev drug combination aimed at treating muscle-invasive bladder cancer. This designation, which shortens the review period, is granted to drugs that may significantly improve treatment for serious diseases. The FDA's target action date for the applications is August 17. If approved, this regimen would be the first perioperative treatment for muscle-invasive bladder cancer, regardless of cisplatin eligibility, potentially establishing a new standard of care.

- Merck, Pfizer, and Astellas Pharma have received U.S. FDA priority review for expanded approval of their Keytruda and Padcev combination for muscle-invasive bladder cancer patients eligible for cisplatin-based chemotherapy.  
- The FDA's designation aims to expedite the review process, with a target action date set for August 17.  
- If approved, this regimen would be the first perioperative treatment option for all muscle-invasive bladder cancer patients, potentially establishing a new standard of care.

MorningStar

Merck

Merck, Pfizer, Astellas Drug Combo Gets Speedy FDA Review in Bladder Cancer

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility | PFE Stock News

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility | PFE Stock News

Astellas Pharma (OTCMKTS:ALPMY) is set to release its earnings on April 24, with analysts expecting earnings of $0.1775 per share and revenue of $3.2836 billion. The company previously reported $0.44 EPS, exceeding estimates. Currently, Astellas Pharma's stock is down 1.6%, trading at $16.19, with a market cap of $29.30 billion. Analyst ratings vary, with one strong buy and four hold ratings. Astellas focuses on developing prescription medicines in various therapeutic areas, including oncology and urology.

Astellas Pharma(ALPMY.US)

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | PFE Stock News

SMC backs first-line metastatic bladder cancer combination after trial results

Astellas Pharma Inc. (TSE:4503) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy

Merck, Pfizer, Astellas Drug Combo Gets Speedy FDA Review in Bladder Cancer

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility | PFE Stock News

Astellas Pharma (ALPMY) Projected to Post Earnings on Friday